NCT02035332已完成不适用
A Two-Phase Clinical Study of the Minerva AURORA Ablation System
Minerva Surgical, Inc.6 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2011年5月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 23
- 试验地点
- 6
- 主要终点
- Reduction in Menstrual Blood Loss to Normal Levels at 12-months
研究概览
简要总结
The primary objective of this study is to evaluate the use of the Aurora Ablation System in reducing menstrual blood loss at 12 months post-treatment. The occurrence of adverse events will be assessed along with an assessment of the reduction of uterine bleeding as measured by a pictorial blood loss assessment chart (PBLAC) or menstrual diary.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 50 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Refractory menorrhagia with no definable organic cause (abnormal uterine bleeding)
- •Female subject from age 35 to 50 years
- •Uterine sound measurement of 6.0cm to 10.0cm (external os to internal fundus)
- •A minimum PBLAC score of >150 for 3 months prior to study enrollment; OR, A minimum PBLAC score >150 for one month for women who either
- •had at least 3 prior months documented failed medical therapy; or
- •had a contraindication to medical therapy; or
- •refused medical therapy
- •Premenopausal at enrollment as determined by FSH measurement ≤ 40 IU/ml
- •Not pregnant and no desire to conceive at any time
- •Patient agrees not to use hormonal contraception or any other medical intervention for bleeding during the study
- •Able to provide written informed consent using a form that has been approved by the reviewing IRB/EC
- •Subject agrees to follow-up exams and data collection, including ability to accurately use menstrual diaries
- •Subject who is literate or demonstrates an understanding on how to use menstrual diaries
排除标准
- •Pregnancy or subject with a desire to conceive
- •Complex endometrial hyperplasia as confirmed by histology
- •Presence of active endometritis
- •Active pelvic inflammatory disease
- •Active sexually transmitted disease (STD)
- •Presence of bacteremia, sepsis, or other active systemic infection
- •Active infection of the genitals, vagina, cervix, uterus or urinary tract at the time of the procedure
- •Known/suspected gynecological malignancy within the past 5 years
- •Known clotting defects or bleeding disorders
- •Untreated/unevaluated cervical dysplasia
- •Known/suspected abdominal/pelvic cancer
- •Prior uterine surgery (except low segment cesarean section) that interrupts the integrity of the uterine wall (e.g., transmural myomectomy or classical cesarean section)
- •Previous endometrial ablation procedure
- •Currently on medications that could thin the myometrial muscle, such as long-term steroid use
- •Currently on anticoagulants
- •Abnormal or obstructed cavity as confirmed by hysteroscopy or SIS, specifically:
- •Septate or bicornuate uterus or other congenital malformation of the uterine cavity
- •Pedunculated or submucosal myomas distorting the uterine cavity
- •Polyps likely to be the cause of the subject's menorrhagia
- •Intramural or subserosal myomas that distort the uterine cavity
- •Presence of an intrauterine device (IUD)
- •Subject currently on hormonal birth control therapy or unwilling to use a non-hormonal birth control post-ablation.
- •Any general health condition which, in the opinion of the Investigator, could represent an increased risk for the subject
- •Any subject who is participating in any other research of an investigational drug or device that has not yet completed the primary endpoint evaluation.
结局指标
主要结局
Reduction in Menstrual Blood Loss to Normal Levels at 12-months
时间窗: 12 Months
Number of subjects in whom menstrual blood loss was reduced to normal or below normal levels at 12 months, as measured by a pictorial blood loss assessment chart (PBLAC) score of \<=75. A score of 0 represents no bleeding.
次要结局
- Procedure Time(Day of procedure)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
不适用
ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial FibrillationLongstanding Persistent Atrial FibrillationPersistent Atrial FibrillationNCT01694563AtriCure, Inc.365
已完成
不适用
Evaluation for the Characterization of the Safety Profile of the DiamondTemp™ System for Fast Treatment of Patients With Atrial FibrillationAtrial FibrillationNCT03626649Medtronic Cardiac Rhythm and Heart Failure60
Unknown
不适用
Safety & Performance of the Centauri System for Patients With Atrial FibrillationAtrial FibrillationNCT04652778Galaxy Medical, Inc.15
进行中（未招募）
不适用
Radial Ablation for the Control of Persistent Atrial FibrillationPersistent Atrial FibrillationNCT04662489Fundacion para la Innovacion en Biomedicina (FIBMED)244
已完成
不适用
ABLATOR Brazil - Ablation Observational Study (Registry)Atrial FibrillationNCT03041233Abbott Medical Devices833